Map Shows States Where Tarantulas Are Roaming for Mating Season
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
It's almost tarantula mating season, and in certain states, tens of thousands of tarantulas are expected to crawl out of their burrows to look for mates.
Whether you're an arachnophobe or an arachnophile, here's what you need to know about tarantula mating season and the states where the eight-legged creatures can be found.
Why It Matters
Tarantula mating season typically takes place from late August to October. High temperatures and moisture drive the creatures from their burrows, and males go out to search for partners.
While tarantulas in the U.S. are generally not aggressive or harmful to humans, public portrayals of the large spiders—which generally measure about 4 inches or more—may inspire fear in some. Knowing more about the creatures could help relieve those concerns.
Which States Have Tarantulas?
According to the World Population Review, tarantulas are present in these 13 U.S. states:
Arizona
Arkansas
California
Colorado
Florida
Kansas
Louisiana
Missouri
Nevada
New Mexico
Oklahoma
Texas
Utah
Generally speaking, tarantulas prefer dry climates and live in Western and Southwestern states. However, they can be found in other states, and their location can depend on the species of tarantula.
What Kinds of Tarantulas Are in the U.S.?
The U.S. is home to about 29 species of tarantula, which primarily belong to the Theraphosidae family.
Here are some of the tarantulas that can be found in the country:
Aphonopelma hentzi—Texas brown tarantula. This is one of the most common species in the U.S. It is found in multiple states and reaches a 4- to 5-inch leg span.
Aphonopelma chalcodes—desert blonde tarantula. Native to Arizona, this tarantula inhabits desert regions and is known for its long life span.
Aphonopelma iodius—Great Basin blonde tarantula. Found in the California, Nevada and Utah deserts, females of this species can live for more than 30 years in captivity.
Aphonopelma anax—Texas tan tarantula. This species is native to southern Texas and northern Mexico, and it is one of the largest species in the U.S., reaching a 5- to 6-inch leg span.
Generally, tarantulas that are seen out and about are males as females are "homebodies who don't travel far from their individual burrows," according to the National Park Service.
Females live longer than males, sometimes up to 25 years while males live up to 10 years. This is partly because of males going on their mating journeys and encountering danger on the way.
A tarantula walks at El Impenetrable National Park, Chaco province, Argentina, on October 28, 2022.
A tarantula walks at El Impenetrable National Park, Chaco province, Argentina, on October 28, 2022.
LUIS ROBAYO/AFP via Getty Images
Are Tarantulas Dangerous to People?
According to the National Park Service, tarantulas are not aggressive or deadly, despite portrayals in pop culture.
The service describes them as docile, adding that though they are capable of biting a person, this mostly happens if they are harassed, and bites are rare. Additionally, their venom is not considered to be toxic to humans.
What Happens Next
The mating season is set to last until the fall. According to World Population Review, "if you see a tarantula in your home, you should not kill it. Keep in mind that tarantulas are going to kill a lot of the most common pests that you might find in your home."
The data site added, "If you feel like you can do so safely, try to catch it in a container. Then, release it in the wild."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
4 hours ago
- Los Angeles Times
It's tarantula mating season. Where you can spot the spider and how to avoid getting bit
If you suffer from arachnophobia, this is the time of year when you're most likely to run into one of your worst nightmares: a tarantula. It's mating season for most of the 29 species of tarantulas in the United States, 10 of which can be found in California, according to Los Padres National Forest. Around this time, tarantulas tend to leave their burrows to hunt for a mate — and they will travel up to 20 miles on their eight fuzzy legs to make a love connection. In Southern California, the two most common species are the Mojave blonde tarantula Aphonopelma iodius, which resides in the Mojave desert area, and the California ebony tarantula Aphonopelma eutylenum, which lives in the south and eastern regions of San Diego and Imperial counties, said Danny McCamish, senior environmental scientist for the California State Parks. During mating season, which begins in August and can last until December, male tarantulas leave their burrows in search of a mate. 'This highly visible behavior contrasts sharply with their otherwise cryptic, burrow-dwelling lifestyle,' said McCamish. Outside of mating season, tarantulas only emerge at night to hunt. 'Mating season for tarantulas is not uniform across the United States,' McCamish said. 'Instead, it depends heavily on regional climate, elevation and species-specific biology.' During mating season, tarantula sightings are common during dusk and nighttime hours, especially following warm days and before seasonal rains, McCamish said. They can be spotted moving around in chaparral and shrub but also in the deserts and mountain areas, said Doug Yanega, senior scientist at UC Riverside's Entomology Research Museum. One indicator of a possible tarantula sighting is a Tarantula hawk wasp buzzing around. This wasp hunts the spider to feed its offspring, according to the National Parks Service. The large blue-black wasps with bright orange wings are 'a much better way to estimate the spider population than trying to actually find the spiders, which are intensely secretive,' Yanega said. McCamish said some of the best-known locations for observing the California ebony tarantula include: Experts say the male spiders may travel up to 20 miles throughout the mating season to find a connection, but the distance depends on the weather, food availability and other environmental conditions. While this is a solitary and competitive journey, you might wander across a swarm of tarantulas who happen to emerge at the same time. 'Anecdotally, people can experience this 'horde' or 'swarm' in the desert during mating season late at night, if conditions are right, when hundreds can be seen crossing remote desert roads slowly on their mating search, McCamish said. When a male locates a female tarantula, he 'initiates a courtship ritual involving rhythmic tapping and vibration to signal his presence and avoid predation,' McCamish said. If the female is receptive, mating occurs. 'Males don't live very long, and females often aggressively rebuff potential mates, so small or weak males may never successfully reproduce,' Yanega added. On average, males live seven to 10 years, whereas females can reach 20 to 25 years or more, according to experts. After mating, the female may eat her counterpart, which is why some males try to escape. The female will then store the sperm in structures called spermathecae and eventually construct an egg sac where the eggs remain until they hatch the following spring or summer, said Sarah Crews, from the California Academy of Sciences' department of entomology. The baby tarantulas are known as 'spiderlings.' 'The spiderlings probably hang out for a bit, then disperse and make their own burrows, likely not traveling too far,' Crews said. Tarantulas are harmless unless grabbed. Researchers say their bodies are covered with 'irritant hairs' that, if touched, can cause dermatitis and a rash. When a spider needs to protect itself from a predator, it rubs its hairs to ward off the danger. 'This is why you sometimes see tarantulas with 'bald spots,'' Crews said. 'They do it when they are stressed, so if you come across one and it starts doing that, best to leave it alone ... while it won't hurt humans, you don't want to stress out the poor guy — he has enough problems at this point'. Tarantulas are often vilified in movies, but they are actually shy, slow-moving and reluctant to bite. Native tarantulas in the United States pose no serious threat to humans and only bite if severely provoked, McCamish said. The venom from a tarantula bite typically won't kill a human, but it can cause minor pain, swelling or itching.
Newsweek
13 hours ago
- Newsweek
PTSD Drug Discovery May Help Patients Let Go of Trauma
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A promising new drug could help people living with post-traumatic stress disorder (PTSD) finally let go of trauma. This is the discovery of scientists at the Institute of Basic Science (IBS) and Ewha Womans University in South Korea who have identified a new brain mechanism driving the mental health condition—and a drug with the potential to counteract its effects. The team has shown for the first time that "excessive" gamma-aminobutyric acid (GABA)—the brain's primary neurotransmitter—produced by star-shaped support cells in the brain known as "astrocytes" impairs the brain's ability to extinguish fear memories. This inability to forget traumatic memories even after a long period of time is distinct to PTSD and has posed a major hurdle for treatment. Current medications targeting serotonin receptors offer limited relief for only a subset of patients, the authors said. "Current FDA-approved treatments for PTSD are mainly SSRIs, which focus on reducing general symptoms like anxiety and mood instability," study author Dr. Woojin Won told Newsweek. "However, only about 20–30 percent of patients achieve full remission, which is often unsatisfactory. Our approach is fundamentally different." Woman with head in hands in dark room. Woman with head in hands in dark room. Domepitipat/Getty Images Won continued: "While prefrontal cortex (PFC) dysfunction has been consistently reported in PTSD, the role of GABAergic mechanisms in this dysfunction has not been fully explored." The researchers found that a brain-permeable drug called KDS2010, which selectively blocks an enzyme called 'monoamine oxidase B' (MAOB) responsible for this abnormal GABA production, can reverse PTSD-like symptoms in mice. "It targets the pathological reactive astrocyte-derived GABA at the source," said Won. "Unlike traditional MAO inhibitors, which can have off-target effects and are irreversible, KDS2010 is highly selective, reversible, and brain-penetrant, making it safer and more targeted." They report the drug has already passed Phase 1 safety trials in humans, which makes it a "strong candidate" for future PTSD treatments. GABA can be a positive thing, helping to regulate motor function, sensory processing and emotional stability. It can also offer calming effects, including helping to reduce anxiety and stress by controlling overactive neurons. "However," Won explained, "GABA does not act uniformly across the brain, and its outcome varies depending on the target circuit. "While GABA is generally calming, in this context [of the researcher's findings], it was silencing a circuit that the brain needs to overcome fear. This highlights that the effect of GABA is not simply good or bad, but it critically depends on where it acts and what neural circuits are involved." Digital illustration showing brain waves and activity. Digital illustration showing brain waves and activity. selvanegra/Getty Images The study focused on the medial prefrontal cortex (mPFC), a region of the brain critical for regulating fear. It found that PTSD patients had unusually high levels of GABA and reduced cerebral blood flow in this area, based on brain imaging studies of more than 380 participants. On the other hand, GABA levels decreased in patients who showed clinical improvement, suggesting the chemical has a central role in recovery. To unearth the origin of the excess GABA, the researchers examined postmortem human brain tissue and used PTSD-like mouse models. They discovered that astrocytes, not neurons, were producing abnormal amounts of GABA via the MAOB enzyme. This astrocyte-derived GABA impaired neural activity, blocking the brain's ability to forget traumatic memories. "This inspired us to investigate astrocytic GABA dysregulation as a potential driver of PTSD pathology, and ultimately, as a novel therapeutic target," said Won. Explaining further how "excessive" GABA in PTSD is produced, he added: "Trauma and stress might increase putrescine metabolism, which raises the levels of MAOB's presubstrate, leading to more GABA production. "At the same time, the enzyme that breaks down GABA, ABAT, is reduced. Together, this combination causes the accumulation of astrocytic GABA and excessive tonic inhibition in key brain regions like the PFC." When the team administered KDS2010, "a highly selective, reversible MAOB inhibitor" developed at IBS, the mice showed normalized brain activity and were able to extinguish fear responses. The promising drug reduced GABA levels, restored blood flow in the mPFC, and re-enabled memory extinction mechanisms. This confirms astrocytic MAOB as a central driver of PTSD symptoms and MAOB inhibition as a viable therapeutic path. The researchers flagged a major challenge of the study was linking clinical findings in humans with cellular mechanisms in the lab. They addressed this by applying a "reverse translational" strategy, beginning with clinical brain scans and moving backward to identify the cellular source of dysfunction. They then confirmed the mechanism and tested drug effects in animal models. This led to a new understanding of how glial cells—non-neuronal cells long thought to be passive—actively shape psychiatric symptoms. Would this type of drug be used alongside other methods like talking therapy for PTSD? "DS2010 alone has a strong potential to restore brain function by normalizing astrocytic GABA and improving fear extinction. However, we think that combining it with psychotherapy, especially exposure-based therapy, could create even greater synergy. By reducing abnormal inhibition in fear extinction circuits, KDS2010 may help the brain become more responsive to therapeutic input," Won explained. How would it be administered? "KDS2010 is an orally available small molecule. In preclinical and early-phase clinical studies, it has been administered once daily in capsule or liquid form. This makes it highly feasible for long-term outpatient use, similar to antidepressants." What about side effects? "In the Phase 1 clinical trial, KDS2010 was found to be well tolerated, with no serious adverse effects reported, even at higher doses. This safety is largely due to its selectivity for MAOB and its reversible mechanism, which avoids the long-term enzyme compensation seen with older MAO inhibitors. Nevertheless, larger trials in PTSD patients will be needed to fully assess tolerability and any rare side effects." Won said the drug is currently undergoing Phase 2 trials for other neurological disorders, which means its safety profile is already being tested extensively in patients. "Because of this, we believe it could reach the public faster than many other new drugs. If future trials for PTSD are successful and regulatory steps proceed smoothly, it could become available within a few years. Importantly, KDS2010 is part of a broader platform that may also be useful for treating other disorders involving astrocytic dysfunction, such as Parkinson's and Alzheimer's disease." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about PTSD? Let us know via health@ Reference Yoon, S., Won, W., Lee, S., Han, K., Ha, E., Lee, J., Hyeon, S. J., Joo, Y., Hong, H., Lee, H., Song, Y., Park, K. D., Huber, B. R., Lee, J., Edden, R. A. E., Suh, M., Ryu, H., Lee, C. J., & Lyoo, I. K. (2025). Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder. Signal Transduction and Targeted Therapy, 10(1), 240.
Newsweek
16 hours ago
- Newsweek
Hard-to-Treat Cancers Respond to New Therapy
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A promising new combination therapy is offering new hope for patients with hard-to-treat cancers. This is thanks to scientists at the Fralin Biomedical Research Institute in Virginia who have identified a potential target for experimental drugs that block PRMT5—a naturally occurring enzyme some tumors rely more on for survival. The study could help guide the development of new therapies for some treatment-resistant lung, brain and pancreatic cancers, according to the researchers. "Using genetic screening, we found a new drug combination that seemingly works," said paper author and cancer biologist professor Kathleen Mulvaney in a statement. A 3D illustration of DNA and cancer cells. A 3D illustration of DNA and cancer cancer is by far the most fatal type of cancer in the US, accounting for about one in five of all cancer deaths. Meanwhile, the five-year survival rate is less than 15 percent for pancreatic cancer patients (although this can vary depending on the stage of cancer) and even lower for glioblastoma, a fast growing type of brain tumor. While treatment options are available, the need for new types is also clear. "With one drug alone, tumors can become resistant really quickly," Mulvaney said. "In all cases, the combination is better at killing than the single agents." The findings suggest the PRMT5 inhibitor could be a powerful new approach for these hard-to-treat cancers. Many of these types of solid tumors share a genetic trait—they lack the genes CDKN2A and MTAP. Both of these are important as they suppress tumors and help to regulate cell growth. Without them, the cancers become dependent on PRMT5 and potentially vulnerable to drugs that lock the enzyme. "It's very difficult to make a drug against the absence of something, so the discovery that PRMT5 is a target we can make a drug against is very exciting to treat CDKN2A/MTAP deleted cancers," Mulvaney told Newsweek. "A new revolutionary class of inhibitors, referred to as MTA-cooperative PRMT5 inhibitors, has shown promising results in ongoing early phase clinical trials," the researchers also explained in the paper. "Nonetheless, effective cancer treatment typically requires therapeutic combinations to improve response rates and defeat emergent resistant clones. Thus, we sought to determine whether perturbation [disrupting or altering] of other pathways could improve the efficacy of MTA-cooperative PRMT5 inhibitors." Doctor showing smiling patient a lung x-ray scan image. Doctor showing smiling patient a lung x-ray scan image. stefanamer/Getty Images To inform their research, the scientists analyzed genetic data from thousands of cancer patients available through the cBioPortal, an open-access resource. They applied a gene-editing technology called CRISPR to look at biological pathways across a range of samples to determine which genes make cancer cells more vulnerable to PRMT5 inhibitors and which combinations could improve response and long-term outcomes. Mulvaney estimates that around five percent of all cancer patients—some 80,000–100,000 per year in the US—could benefit from the newly identified therapies. Using PRMT5 inhibitors with drugs that block a communication system that tells cancer cells when to grow, divide or shut down the—'MAP kinase pathway'—the scientists identified potential treatments for clinical trials. "We also discovered a number of genes that interact with PRMT5 signaling in cancer that were not previously known," said Mulvaney. As well as hopefully helping to lead to better lung, brain and pancreatic treatments, the therapy shows promise for other types of cancer. This includes melanoma—the most dangerous type of skin cancer—and mesothelioma—mainly affecting the lining of the lungs, though can also affect the lining of the stomach, heart of testicles. In both animal models and cell cultures derived from patient tissue, lab members saw success after testing potential therapies. Mulvaney explained that in the lung cancer models, for example, 75 percent of mice ended up with no detectable tumors after treatment. These responses were stable after drug withdrawal. "In all cases, the combination is better at killing cancer cells than the single agents," she said. "Only the combinations led to complete regressions." Mulvaney explained further, "We've only tested dosing concurrently in preclinical models. It will be interesting to test whether the drug dosing order matters e.g., if we can treat with one compound before adding the other for further benefit or whether concurrent dosing is better." Could there be increased side effects from the new therapy? "In the preclinical mouse models, the combination dosing was well tolerated; no weight loss was detected in the mice. It will be important to monitor potential side effects of the combination in the clinical trials." The researchers concluded in the paper, "Overall, this study identifies therapeutic combinations with MTA-cooperative PRMT5 inhibitors that may offer significant benefit to patients." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about cancer? Let us know via health@ Reference Knoll, N., Masser, S., Bordas, B., Ebright, R. Y., Li, G., Kesar, D., Destefanis, E., Kania, N., Rodriguez, D. J., Jen, J., Zagar, S. E., Mensah, C., Chen, Z., Moffitt, S. J., Enakireru, E. M., He, Y., Feng, B., Chokshi, M. K., Jin, C. Y., ... Mulvaney, K. M. (2025). CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-deleted Cancer. Cancer Research.
